JAK mutations in high-risk childhood acute lymphoblastic leukemia - PubMed (original) (raw)
. 2009 Jun 9;106(23):9414-8.
doi: 10.1073/pnas.0811761106. Epub 2009 May 22.
Jinghui Zhang, Richard C Harvey, J Racquel Collins-Underwood, Brenda A Schulman, Letha A Phillips, Sarah K Tasian, Mignon L Loh, Xiaoping Su, Wei Liu, Meenakshi Devidas, Susan R Atlas, I-Ming Chen, Robert J Clifford, Daniela S Gerhard, William L Carroll, Gregory H Reaman, Malcolm Smith, James R Downing, Stephen P Hunger, Cheryl L Willman
Affiliations
- PMID: 19470474
- PMCID: PMC2695045
- DOI: 10.1073/pnas.0811761106
JAK mutations in high-risk childhood acute lymphoblastic leukemia
Charles G Mullighan et al. Proc Natl Acad Sci U S A. 2009.
Abstract
Pediatric acute lymphoblastic leukemia (ALL) is a heterogeneous disease consisting of distinct clinical and biological subtypes that are characterized by specific chromosomal abnormalities or gene mutations. Mutation of genes encoding tyrosine kinases is uncommon in ALL, with the exception of Philadelphia chromosome-positive ALL, where the t(9,22)(q34;q11) translocation encodes the constitutively active BCR-ABL1 tyrosine kinase. We recently identified a poor prognostic subgroup of pediatric BCR-ABL1-negative ALL patients characterized by deletion of IKZF1 (encoding the lymphoid transcription factor IKAROS) and a gene expression signature similar to BCR-ABL1-positive ALL, raising the possibility of activated tyrosine kinase signaling within this leukemia subtype. Here, we report activating mutations in the Janus kinases JAK1 (n = 3), JAK2 (n = 16), and JAK3 (n = 1) in 20 (10.7%) of 187 BCR-ABL1-negative, high-risk pediatric ALL cases. The JAK1 and JAK2 mutations involved highly conserved residues in the kinase and pseudokinase domains and resulted in constitutive JAK-STAT activation and growth factor independence of Ba/F3-EpoR cells. The presence of JAK mutations was significantly associated with alteration of IKZF1 (70% of all JAK-mutated cases and 87.5% of cases with JAK2 mutations; P = 0.001) and deletion of CDKN2A/B (70% of all JAK-mutated cases and 68.9% of JAK2-mutated cases). The JAK-mutated cases had a gene expression signature similar to BCR-ABL1 pediatric ALL, and they had a poor outcome. These results suggest that inhibition of JAK signaling is a logical target for therapeutic intervention in JAK mutated ALL.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Fig. 1.
Primary structure of JAK1, JAK2, and JAK3 showing the location of missense (▼) and insertion/deletion (▲) mutations. FERM, band 4.1 ezrin, radixin, and moesin domain; SH2, src-homology domain; JH2, pseudokinase domain; and JH1, kinase domain.
Fig. 2.
Functional effects of JAK mutations. (A) Ba/F3-EpoR cells were transduced with retroviruses expressing wild-type or mutant Jak2 alleles and cultured in the absence of cytokine. Each Jak2 mutant examined resulted in cytokine-independent growth. Untransduced cells and cells transduced with wild-type mJak2 remained cytokine-dependent. Mean ± SDs of triplicates are shown. (B) Transduction of Ba/F3-EpoR cells with retrovirus expressing mJak1 S646F resulted in factor independence. (C) Ba/F3-EpoR cells transduced with wild-type or mutant Jak2 were cultured without cytokine in the presence of increasing concentrations of Jak inhibitor I. Each mutation was sensitive to Jak inhibition. The _BCR-ABL1_-positive cell line K562 is shown as a control. (D) Growth of Ba/F3 cells transduced with S646F was inhibited by Jak inhibitor I. (E) Western blots showing activation of JAK-STAT signaling in Ba/F3-EpoR cells transduced with each mutant Jak allele. Cells were cultured without erythropoietin for 15 h and then harvested for blotting before and after 15 min of erythropoietin at 5 units/mL. Each mutation resulted in constitutive Jak2 and Stat5 phosphorylation that was augmented by pulsed erythropoietin (shown for Jak2 617F and 683G). The Jak2 kinase domain mutations showed less constitutive Jak-Stat activation than the pseudokinase domain mutations. Epo, erythropoietin; WT, wild type. (F) Western blots demonstrating abrogation of Jak-Stat activation by Jak inhibitor I. Ba/F3-EpoR cells transduced with each Jak allele were grown in the absence of cytokine, then harvested after 5 h of exposure to 5 mM Jak inhibitor I or vehicle (DMSO).
Fig. 3.
Phosphoflow cytometry analysis of Jak-Stat activation in Ba/F3-EpoR cells transduced with Jak2 retroviral constructs. Transduced cells were serum-starved and cytokine-starved and then stimulated either with erythropoietin (Epo; A and B) or pervanadate (PV; C and D), either without pharmacologic Jak inhibition (A and C) or after administration of the Jak2 inhibitor XL019 (B and D). (A) Activation of Jak-Stat phosphorylation with erythropoietin stimulation. Notably, Jak2 phosphorylation was evident for Jak2 pseudokinase mutant alleles but not the kinase domain mutants. (B) Signaling was abrogated in control and mutants treated with XL019 with subsequent erythropoietin stimulation. (C) Marked Jak2 and Stat5 phosphorylation was observed for each mutant after pervanadate stimulation. (D) Jak2 and Stat5 signaling was preferentially abrogated in mutants treated with XL019 with subsequent pervanadate stimulation.
Fig. 4.
Gene expression profile and outcome of JAK-mutated B-progenitor ALL. (A) Gene set enrichment analysis demonstrates significant enrichment of the BCR-ABL1 gene expression signature in JAK-mutated ALL. (B) Heatmap of the enriched BCR-ABL1 up-regulated gene set in the P9906 cohort, showing overexpression of BCR-ABL1 up-regulated genes in JAK-mutated ALL. Notably, several cases lacking JAK mutations also have a BCR-ABL1 signature, suggesting the presence of additional kinase mutations in these cases. (C and D) JAK mutation and IKZF1 alteration are associated with a high incidence of events (C) and relapse (D).
Similar articles
- Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E, Hornakova T, Springuel L, Degryse S, Gielen O, Cools J, Constantinescu SN, Flex E, Tartaglia M, Renauld JC, Knoops L. Losdyck E, et al. J Biol Chem. 2015 Nov 27;290(48):29022-34. doi: 10.1074/jbc.M115.670224. Epub 2015 Oct 7. J Biol Chem. 2015. PMID: 26446793 Free PMC article. - Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Boer JM, Steeghs EM, Marchante JR, Boeree A, Beaudoin JJ, Beverloo HB, Kuiper RP, Escherich G, van der Velden VH, van der Schoot CE, de Groot-Kruseman HA, Pieters R, den Boer ML. Boer JM, et al. Oncotarget. 2017 Jan 17;8(3):4618-4628. doi: 10.18632/oncotarget.13492. Oncotarget. 2017. PMID: 27894077 Free PMC article. - Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.
Loh ML, Zhang J, Harvey RC, Roberts K, Payne-Turner D, Kang H, Wu G, Chen X, Becksfort J, Edmonson M, Buetow KH, Carroll WL, Chen IM, Wood B, Borowitz MJ, Devidas M, Gerhard DS, Bowman P, Larsen E, Winick N, Raetz E, Smith M, Downing JR, Willman CL, Mullighan CG, Hunger SP. Loh ML, et al. Blood. 2013 Jan 17;121(3):485-8. doi: 10.1182/blood-2012-04-422691. Epub 2012 Dec 4. Blood. 2013. PMID: 23212523 Free PMC article. - The biology of Philadelphia chromosome-like ALL.
Roberts KG. Roberts KG. Best Pract Res Clin Haematol. 2017 Sep;30(3):212-221. doi: 10.1016/j.beha.2017.07.003. Epub 2017 Jul 6. Best Pract Res Clin Haematol. 2017. PMID: 29050694 Review. - Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia.
Franca R, Kuzelicki NK, Sorio C, Toffoletti E, Montecchini O, Poropat A, Rabusin M, Curci D, Paladin D, Stocco G, Decorti G. Franca R, et al. Curr Med Chem. 2018;25(24):2811-2825. doi: 10.2174/0929867324666170727101932. Curr Med Chem. 2018. PMID: 28748759 Review.
Cited by
- Clonal evolution of the 3D chromatin landscape in patients with relapsed pediatric B-cell acute lymphoblastic leukemia.
Narang S, Ghebrechristos Y, Evensen NA, Murrell N, Jasinski S, Ostrow TH, Teachey DT, Raetz EA, Lionnet T, Witkowski M, Aifantis I, Tsirigos A, Carroll WL. Narang S, et al. Nat Commun. 2024 Aug 28;15(1):7425. doi: 10.1038/s41467-024-51492-6. Nat Commun. 2024. PMID: 39198446 Free PMC article. - Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, Kegyes D, Onaciu A, Gulei D, Ghiaur G, Einsele H, Croce CM. Tomuleasa C, et al. Signal Transduct Target Ther. 2024 Aug 14;9(1):201. doi: 10.1038/s41392-024-01899-w. Signal Transduct Target Ther. 2024. PMID: 39138146 Free PMC article. Review. - Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms.
Gorantla SP, Prince G, Osius J, Dinesh DC, Boddu V, Duyster J, von Bubnoff N. Gorantla SP, et al. Front Oncol. 2024 Jul 18;14:1430833. doi: 10.3389/fonc.2024.1430833. eCollection 2024. Front Oncol. 2024. PMID: 39091915 Free PMC article. - Increased AID results in mutations at the CRLF2 locus implicated in Latin American ALL health disparities.
Rangel V, Sterrenberg JN, Garawi A, Mezcord V, Folkerts ML, Calderon SE, Garcia YE, Wang J, Soyfer EM, Eng OS, Valerin JB, Tanjasiri SP, Quintero-Rivera F, Seldin MM, Masri S, Frock RL, Fleischman AG, Pannunzio NR. Rangel V, et al. Nat Commun. 2024 Jul 27;15(1):6331. doi: 10.1038/s41467-024-50537-0. Nat Commun. 2024. PMID: 39068148 Free PMC article. - Histidine re-sensitizes pediatric acute lymphoblastic leukemia to 6-mercaptopurine through tetrahydrofolate consumption and SIRT5-mediated desuccinylation.
Dong N, Ma HX, Liu XQ, Li D, Liu LH, Shi Q, Ju XL. Dong N, et al. Cell Death Dis. 2024 Mar 14;15(3):216. doi: 10.1038/s41419-024-06599-5. Cell Death Dis. 2024. PMID: 38485947 Free PMC article.
References
- Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030–1043. - PubMed
- Mullighan CG, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758–764. - PubMed
- Mullighan CG, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110–114. - PubMed
- Nachman JB, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663–1671. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 CA118100/CA/NCI NIH HHS/United States
- U01 CA114762/CA/NCI NIH HHS/United States
- CA114762/CA/NCI NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- U10 CA098413/CA/NCI NIH HHS/United States
- N01-C0-12400/PHS HHS/United States
- CA098543/CA/NCI NIH HHS/United States
- T32 HD044331/HD/NICHD NIH HHS/United States
- U01 CA157937/CA/NCI NIH HHS/United States
- U10 CA098543/CA/NCI NIH HHS/United States
- T32 CA128583/CA/NCI NIH HHS/United States
- U10 CA98543/CA/NCI NIH HHS/United States
- U10 CA98413/CA/NCI NIH HHS/United States
- L40 CA142226/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous